BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution

  Revenue for the first fiscal quarter ended September 30, 2017 totaled $385,000 compared to $277,000 for the prior year quarter.

  November 7, 2017

   · 

  8 min read
• Business

  Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update

  At September 30, 2017, Tonix had cash and cash equivalents of $29.3 million. Net cash used in operating activities for the third quarter was $5.0 million.

  November 7, 2017

   · 

  9 min read
• Business

  Aclaris Therapeutics Reports Third Quarter 2017 Financial Results

  As of September 30, 2017, Aclaris had aggregate cash, cash equivalents and marketable securities of $227.8 million compared to $174.1 million as of December 31, 2016.

  November 7, 2017

   · 

  12 min read
• Business

  Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results

  “We are pleased with the progress we achieved during the third quarter, hitting multiple milestones for our lead programs,” said Amit D. Munshi, President and CEO of Arena.

  November 7, 2017

   · 

  16 min read
• Business

  Cogentix Medical Reports Third Quarter Results; Second Highest Quarterly Revenue in Company History

  Third quarter revenue was $13.8M, an increase of 3% over the third quarter of 2016.

  November 7, 2017

   · 

  31 min read
• Business

  Kindred Biosciences Announces Third Quarter 2017 Financial Results

  Kindred Biosciences today announced financial results for the third quarter ended September 30, 2017 and provided updates on its programs.

  November 7, 2017

   · 

  11 min read
• Business

  Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results

  Total net product sales from HETLIOZ and Fanapt were $41.3M in the third quarter of 2017, a 2% decrease compared to $42.1M in the second quarter of 2017 and a 7% increase compared to $38.5M in the third quarter of 2016.

  November 7, 2017

   · 

  28 min read
• Business

  Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update

  For the third quarter of 2017, Rigel reported a net loss of $17.7M, or $0.14 per basic and diluted share, compared to a net loss of $22.6M, or $0.24 per basic and diluted share, in the same period of 2016.

  November 7, 2017

   · 

  15 min read
• Business

  Syndax Pharma Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

  As of September 30, 2017, Syndax had $120.6M in cash, cash equivalents and short-term investments.

  November 7, 2017

   · 

  17 min read
• Business

  Regulus Reports Third Quarter 2017 Financial Results and Recent Events

  Regulus Therapeutics today summarized recent events and reported financial results for the three and nine months ended September 30, 2017.

  November 7, 2017

   · 

  10 min read